Monthly Newsletter

AMSBIO has announced the launch of GMP grade STEM-CELLBANKER® manufactured in strict compliance with Japanese, EU, US, and PICS good manufacturing practice guidelines.

Supplied as a ready-to-use formulation, STEM-CELLBANKER is a chemically defined freezing solution optimised for stem cell and iPS cell storage as well as preservation of other valuable cells. Recent data** supports its unmatched ability for use in cryopreservation of tissues. It is completely free of serum and animal derived component, and contains only US Pharmacopeia, European Pharmacopeia or Japanese Pharmacopeia graded ingredients. A drug master file for STEM-CELLBANKER cryopreservation solution has been registered with the US Food and Drug Administration (FDA). [MF # 15785].

STEM CELLBANKER significantly increases cell viability while maintaining cell pluripotency, normal karyotype and proliferation ability following resuscitation from cryopreservation, even after extended long-term storage. Independent research has demonstrated that hESC, MSCs and iPS cells cryopreserved with STEM CELLBANKER produce significantly higher cell viability (> 90%) over conventional freezing medium, while retaining cell pluripotency, normal karyotype and proliferation ability. Every batch of STEM CELLBANKER cryopreservation medium is performance tested on Jurkat and SK-007 cells. Additional standard evaluations for endotoxins, pH, osmolarity and Mycoplasma contaminants are undertaken to ensure GMP equivalent quality. STEM CELLBANKER enables long term cell storage for greater than 10 years at -80C or -196C.

In a recent study** to determine the best cryopreservation solution to maintain induced pluripotent stem (iPS) cells, a team of researchers from the Okayama University Graduate School of Medicine (Japan) compared 12 kinds of commercially prepared cryopreservation solutions and found that STEM CELLBANKER** outperformed the other 11 solutions. The researchers concluded that STEM CELLBANKER** showed the highest cell viability and proliferation of all the solutions tested and can be widely used as it does not require any special skills to use.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production, CRISPR/Cas9 Genome Editing, lentivirus and adenovirus production, large scale protein production and a comprehensive portfolio of antibody services.

more about AMS biotechnology

more news from AMS biotechnology